Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies
SAN FRANCISCO and SUZHOU, China, April 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of...
Appian Embeds Agentic AI into Business Processes to Deliver Scalable, Governable Enterprise Value
Introducing new AI features and Data Fabric enhancements to deliver real-time insights and measurable impact. SYDNEY, April 30, 2025 /PRNewswire/ -- Appian (NASDAQ: APPN) today announced agentic AI platform enhancements to help organisations build,...
137th Canton Fair Phase 2 Highlights Quality Home Life Through Innovation and Green Thinking
GUANGZHOU, China, April 30, 2025 /PRNewswire/ -- Phase 2 of the 137th China Import and Export Fair (Canton Fair), taking place from April 23 to 27, spans an impressive 515,000 square meters of exhibition space. With 10,313 participating companies,...
Everest Medicines Announces New Drug Application Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis in Hong Kong
SHANGHAI, April 30, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics,...
KT Corp. Files 2024 Annual Report on Form 20-F
SEOUL, South Korea, April 30, 2025 /PRNewswire/ -- KT Corporation (NYSE: KT), South Korea's leading integrated telecommunications and platform service provider, announced that it has filed its Form 20-F Annual Report on April 29th, 2025 for the year...
【C.S Group】: Launches Antcin A-Based Veterinary Drug Initiative Across Taiwan and China
TAIPEI, April 30, 2025 /PRNewswire/ -- Cordyceps Sunshine Biotech Holdings Co., Ltd.【 C.S Group 】 announced a major milestone in veterinary drug development at the "Pharmacological Progress Conference for Taiwanofungus camphoratus Applications in...
Nisun International Enterprise Development Group Co., Ltd Reports Full Year 2024 Financial Results
Highlights Positive Earnings Per Share and Substantial Cash Position of $11.11/share Amidst Challenging Economic Environment SHANGHAI, April 30, 2025 /PRNewswire/ -- Nisun International Enterprise Development Group Co., Ltd ("Nisun International" or...
e& achieves AED 16.9 billion consolidated revenue growing 18.7% YoY in Q1 2025
Consolidated net profit increased to AED 5.4 billion, reflecting a 129.9 per cent increase year-on-year growth. Excluding the impact of Khazna transaction, net profit increased by 19.1 per cent year-on-year. The proceeds of USD 2.2 billion were...